Cost-effectiveness analysis of neoadjuvant immune checkpoint inhibition vs. cisplatin-based chemotherapy in muscle invasive bladder cancer
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Cost-effectiveness analysis of neoadjuvant immune checkpoint inhibition vs. cisplatin-based chemotherapy in muscle invasive bladder cancer
Authors
Keywords
Muscle invasive bladder cancer, Urothelial carcinoma, Neoadjuvant, Immunotherapy, Cost effectiveness analysis
Journal
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
Volume -, Issue -, Pages -
Publisher
Elsevier BV
Online
2021-03-23
DOI
10.1016/j.urolonc.2021.03.004
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Randomized phase III trial of dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin (dd-MVAC) or gemcitabine and cisplatin (GC) as perioperative chemotherapy for muscle invasive urothelial bladder cancer (MIUBC): Preliminary results of the GETUG/AFU V05 VESPER trial on toxicity and pathological responses.
- (2020) Stephane Culine et al. JOURNAL OF CLINICAL ONCOLOGY
- Results from BLASST-1 (Bladder Cancer Signal Seeking Trial) of nivolumab, gemcitabine, and cisplatin in muscle invasive bladder cancer (MIBC) undergoing cystectomy.
- (2020) Shilpa Gupta et al. JOURNAL OF CLINICAL ONCOLOGY
- Maintenance avelumab + best supportive care (BSC) versus BSC alone after platinum-based first-line (1L) chemotherapy in advanced urothelial carcinoma (UC): JAVELIN Bladder 100 phase III interim analysis.
- (2020) Thomas Powles et al. JOURNAL OF CLINICAL ONCOLOGY
- Treatment of muscle‐invasive and advanced bladder cancer in 2020
- (2020) Vaibhav G. Patel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- SWOG S1314: A randomized phase II study of co-expression extrapolation (COXEN) with neoadjuvant chemotherapy for localized, muscle-invasive bladder cancer.
- (2019) Thomas W. Flaig et al. JOURNAL OF CLINICAL ONCOLOGY
- DUTRENEO Trial: A phase II randomized trial of DUrvalumab and TREmelimumab as NEOadjuvant approach in muscle-invasive urothelial bladder cancer (MIBC) patients prospectively selected by immune signature scores.
- (2019) Enrique Grande et al. JOURNAL OF CLINICAL ONCOLOGY
- Comparison of Costs of Radical Cystectomy vs Trimodal Therapy for Patients With Localized Muscle-Invasive Bladder Cancer
- (2019) Stephen B. Williams et al. JAMA Surgery
- Healthcare resource utilization and costs of adverse events among patients with metastatic urothelial cancer in USA
- (2019) Petros Grivas et al. Future Oncology
- Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial
- (2019) Thomas Powles et al. NATURE MEDICINE
- ENERGIZE: a Phase III study of neoadjuvant chemotherapy alone or with nivolumab with/without linrodostat mesylate for muscle-invasive bladder cancer
- (2019) Guru Sonpavde et al. Future Oncology
- Feasibility of Cisplatin-Based Neoadjuvant Chemotherapy in Muscle-Invasive Bladder Cancer Patients With Diminished Renal Function
- (2018) Vadim S. Koshkin et al. Clinical Genitourinary Cancer
- Perioperative chemotherapy for bladder cancer in the general population: Are practice patterns finally changing?
- (2018) Christopher M. Booth et al. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
- Comparing Survival Outcomes and Costs Associated With Radical Cystectomy and Trimodal Therapy for Older Adults With Muscle-Invasive Bladder Cancer
- (2018) Stephen B. Williams et al. JAMA Surgery
- Immune checkpoint inhibitors in urothelial cancer: recent updates and future outlook
- (2018) Dharmesh Gopalakrishnan et al. Therapeutics and Clinical Risk Management
- Pembrolizumab as Neoadjuvant Therapy Before Radical Cystectomy in Patients With Muscle-Invasive Urothelial Bladder Carcinoma (PURE-01): An Open-Label, Single-Arm, Phase II Study
- (2018) Andrea Necchi et al. JOURNAL OF CLINICAL ONCOLOGY
- Early Adoption of Biosimilar Growth Factors in Supportive Cancer Care
- (2018) Xiaoxue Chen et al. JAMA Oncology
- Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
- (2017) Joaquim Bellmunt et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety and Tolerability of PD‐1/PD‐L1 Inhibitors Compared with Chemotherapy in Patients with Advanced Cancer: A Meta‐Analysis
- (2017) Tomohiro F. Nishijima et al. ONCOLOGIST
- Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer: A Systematic Review and Two-Step Meta-Analysis
- (2016) Ming Yin et al. ONCOLOGIST
- The burden of bladder cancer care
- (2014) Matthew Mossanen et al. CURRENT OPINION IN UROLOGY
- Accelerated Methotrexate, Vinblastine, Doxorubicin, and Cisplatin Is Safe, Effective, and Efficient Neoadjuvant Treatment for Muscle-Invasive Bladder Cancer: Results of a Multicenter Phase II Study With Molecular Correlates of Response and Toxicity
- (2014) Elizabeth R. Plimack et al. JOURNAL OF CLINICAL ONCOLOGY
- Neoadjuvant Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin With Pegfilgrastim Support in Muscle-Invasive Urothelial Cancer: Pathologic, Radiologic, and Biomarker Correlates
- (2014) Toni K. Choueiri et al. JOURNAL OF CLINICAL ONCOLOGY
- Treatment of Patients With Metastatic Urothelial Cancer “Unfit” for Cisplatin-Based Chemotherapy
- (2011) Matthew D. Galsky et al. JOURNAL OF CLINICAL ONCOLOGY
- Projections of the Cost of Cancer Care in the United States: 2010-2020
- (2011) A. B. Mariotto et al. JNCI-Journal of the National Cancer Institute
- Disease-Free Survival at 2 or 3 Years Correlates With 5-Year Overall Survival of Patients Undergoing Radical Cystectomy for Muscle Invasive Bladder Cancer
- (2010) Guru Sonpavde et al. JOURNAL OF UROLOGY
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started